ArticleAmerican journal of cardiovascular disease2026
The national and subnational trend of ischemic heart disease in Iran from 1990-2021, with projections for 2040: a modelling study.
Article in American journal of cardiovascular disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic heart disease (IHD) is a leading cause of death in Iran, and monitoring its trends is essential for disease management and achieving Sustainable Development Goal 3.4.
methodsThis study examines the prevalence of IHD in Iran at national and subnational levels and projects future trends to 2040. We retrieved sex-specific IHD data for Iran and its provinces from 1990 to 2021 from the Global Burden of Disease (GBD) Study 2021 and applied the illness-death model (IDM) to estimate age-standardized prevalence rates (ASPRs) by 2040.
resultsIn Iran, the ASPR of IHD decreased until 2009 but began to rise again by 2021. By 2040, prevalence is projected to increase by 16% to 7,336.1 per 100,000 (95% CI: 7,163.9-7,512.4). In 2021, the highest provincial ASPRs were observed in Khuzestan, Yazd, and Alborz; by 2040, Yazd, Khuzestan, and North Khorasan are expected to have the highest rates. Conversely, Hamadan, Sistan and Baluchistan, and West Azarbayejan had the lowest ASPRs in both 2021 and 2040. A similar pattern was observed in both males and females.
conclusionThese findings indicate an upward trend in IHD nationwide and across all provinces by 2040. To lessen the future impact of IHD in Iran, it is crucial to tackle modifiable risk factors, strengthen the healthcare system, and improve prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.